Literature DB >> 28588733

Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences.

Yoshihito Yokoyama1, Tatsuhiko Shigeto1, Rie Miura1, Asami Kobayashi1, Makito Mizunuma1, Aisa Yamauchi1, Masayuki Futagami1, Hideki Mizunuma1.   

Abstract

Protoporphyrin IX (PpIX) levels are crucial to the antitumor action of photodynamic therapy (PDT). In the present study, the underling molecular mechanisms for the variation in PpIX levels in ovarian cancer cells were investigated. Five ovarian cancer cell lines were subcutaneously grafted onto the backs of nude mice. Once tumors had developed, 5-aminolevulinic acid methyl ester hydrochloride (methyl-ALA) was administered intraperitoneally and the tumor was irradiated twice/week. PpIX levels in the tumor were assayed using high-performance liquid chromatography. Enzymes involved in heme synthesis and degradation were screened using a microarray technique. Expression of the glutathione transferase Omega-1 (GSTO1) gene involved in the conversion of PpIX into heme in cells was quantified using the reverse transcription-quantitative polymerase chain reaction. In HTOA, HRA and DISS cells, PDT resulted in significant tumor shrinkage in comparison with the controls. In MCAS and TOV21G cells, no significant alterations in tumor growth were identified compared with the untreated cells. PpIX levels increased significantly in HTOA, DISS and HRA cells compared with in MCAS and TOV21G cells. A comparison of genetic profiles using PDT-sensitive DISS cells and PDT-resistant MCAS cells indicated that MCAS cells exhibited significantly increased levels of δ-aminolevulinate synthase (a rate-limiting enzyme in heme synthesis), heme oxygenase 2 (an enzyme that degrades heme into biliverdin), and biliverdin reductase B (an enzyme that reduces biliverdin into bilirubin) in comparison with DISS cells. The level of GSTO1 expression in HTOA, HRA and DISS cells was ~2.5-fold that in MCAS and TOV21G cells. Sensitivity to PDT is related to PpIX levels in cells. The results of the present study suggested that PpIX tends not to accumulate in PDT-resistant cells despite active heme synthesis and degradation, and that high levels of GSTO1 expression are associated with increased sensitivity to PDT.

Entities:  

Keywords:  5-aminolevulinic acid methyl ester hydrochloride; glutathione transferase Omega-1; ovarian cancer; photodynamic therapy; protoporphyrin IX

Year:  2017        PMID: 28588733      PMCID: PMC5452891          DOI: 10.3892/ol.2017.6095

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Photofrin PDT for early stage esophageal cancer: a new standard of care?

Authors:  Alan G Casson
Journal:  Photodiagnosis Photodyn Ther       Date:  2009-10-02       Impact factor: 3.631

2.  Photoradiation in the treatment of recurrent breast carcinoma.

Authors:  T J Dougherty; G Lawrence; J H Kaufman; D Boyle; K R Weishaupt; A Goldfarb
Journal:  J Natl Cancer Inst       Date:  1979-02       Impact factor: 13.506

3.  The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.

Authors:  Kyeong-Ah Jung; Bo-Hyun Choi; Mi-Kyoung Kwak
Journal:  Mol Pharmacol       Date:  2014-12-22       Impact factor: 4.436

4.  Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.

Authors:  Margaretha Akeson; Britt-Marie Zetterqvist; Kalle Dahllöf; Mats Brännström; György Horvath
Journal:  Acta Obstet Gynecol Scand       Date:  2008       Impact factor: 3.636

5.  Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.

Authors:  Y Kikuchi; I Kizawa; K Oomori; M Miyauchi; T Kita; M Sugita; Y Tenjin; K Kato
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Authors:  G Hofstetter; N Concin; I Braicu; R Chekerov; J Sehouli; I Cadron; T Van Gorp; F Trillsch; S Mahner; H Ulmer; C Grimm; D Cacsire Castillo-Tong; R Zeillinger; A G Zeimet; I Vergote
Journal:  Gynecol Oncol       Date:  2013-07-20       Impact factor: 5.482

7.  Current role of laser and photodynamic therapy in gastrointestinal tumors and analysis of a 10-year experience.

Authors:  P Spinelli; M Dal Fante; A Mancini
Journal:  Semin Surg Oncol       Date:  1992 Jul-Aug

8.  Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers.

Authors:  M Wakui; Yoshihito Yokoyama; H Wang; T Shigeto; M Futagami; H Mizunuma
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-13       Impact factor: 4.553

9.  Hypoxic up-regulation of erythroid 5-aminolevulinate synthase.

Authors:  Thomas Hofer; Roland H Wenger; Marianne F Kramer; Gloria C Ferreira; Max Gassmann
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

10.  Characterization and mutational analysis of omega-class GST (GSTO1) from Apis cerana cerana, a gene involved in response to oxidative stress.

Authors:  Fei Meng; Yuanying Zhang; Feng Liu; Xingqi Guo; Baohua Xu
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more
  3 in total

Review 1.  Which cell death modality wins the contest for photodynamic therapy of cancer?

Authors:  Maria Vedunova; Dmitri V Krysko; Tatiana Mishchenko; Irina Balalaeva; Anastasia Gorokhova
Journal:  Cell Death Dis       Date:  2022-05-13       Impact factor: 9.685

2.  Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties.

Authors:  Martha Baydoun; Olivier Moralès; Céline Frochot; Colombeau Ludovic; Bertrand Leroux; Elise Thecua; Laurine Ziane; Anne Grabarz; Abhishek Kumar; Clémentine de Schutter; Pierre Collinet; Henri Azais; Serge Mordon; Nadira Delhem
Journal:  J Clin Med       Date:  2020-04-21       Impact factor: 4.241

Review 3.  Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy.

Authors:  Yo Shinoda; Daitetsu Kato; Ryosuke Ando; Hikaru Endo; Tsutomu Takahashi; Yayoi Tsuneoka; Yasuyuki Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.